Compliance was examined alternatively in terms of incidence of adherence failure (medication days
Osteoporos Int DOI 10.1007/s00198-006-0179-x
ORIGINAL ARTICLE
Compliance with drug therapy for postmenopausal osteoporosis D. Weycker & D. Macarios & J. Edelsberg & G. Oster
Received: 5 April 2006 / Accepted: 15 May 2006 # International Osteoporosis Foundation and National Osteoporosis Foundation 2006
Abstract Introduction Patient compliance with pharmacotherapy for osteoporosis is typically poor in clinical practice; less frequent dosing with bisphosphonates may improve compliance. Methods Using data from 49 US health plans, we identified all women aged ≥45 years with osteoporosis who initiated therapy with a bisphosphonate, calcitonin, estrogen, or raloxifene. Compliance was examined alternatively in terms of incidence of adherence failure (medication days
